Skip to main content

Table 2 Overall and subgroup meta-analyses of the relationship between mGPS and OS

From: The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

Subgroups Studies/N Patients/N Pooled HR (95% CI, P) Heterogeneity (P, I², Model)
mGPS: high vs. low
 Overall 12 2009 1.504, (1.197–1.891), < 0.0001 0.003, 61.7%, random
 Region     
 East 9 1668 1.597, (1.240–2.056), < 0.0001 0.071, 44.7%, fixed
 West 3 341 1.342, (0.797–2.258), 0.268 0.002, 83.8%, random
 Therapy     
 Chemotherapy 7 932 1.455, (1.048–2.020), 0.025 0.001, 74.2%, random
 Pancreatectomy 5 1077 1.638, (1.247–2.150), < 0.0001 0.345, 10.7%, fixed
mGPS: 1 vs. 0
 Overall 8 4503 1.683, (1.247–2.269), 0.001 < 0.0001, 86.6%, random
 Region     
 East 7 4401 1.711, (1.248–2.347), 0.001 < 0.0001, 88.5%, random
 West 1 102 1.346, (0.585–3.098), 0.485
 Therapy     
 Chemotherapy 6 2968 1.780, (1.297–2.443), < 0.0001 < 0.0001, 83.9%, random
 Pancreatectomy 2 1535 1.521, (0.602–3.838), 0.375 0.001, 91.4%, random
mGPS: 2 vs. 0
 Overall 8 4503 1.899, (1.356–2.660), < 0.0001 < 0.0001, 80.4%, random
 Region     
 East 7 4401 1.833, (1.285–2.615), 0.001 < 0.0001, 82.3%, random
 West 1 102 2.712, (1.252–5.875), 0.011
 Therapy     
 Chemotherapy 6 2968 1.872, (1.174–2.984), 0.008 < 0.0001, 81.5%, random
 Pancreatectomy 2 1535 2.011, (0.941–4.297), 0.078 0.003, 88.3%, rrandom
  1. “–” means not available; N means number